DLA Piper

Pharma

M&A surge triggers high expectations for 2026

A blitz of biopharma activity at the end of March indicates that 2026 will be a prime year for M&A and that the surge seen in Q4 was not a false alarm.

Kevin Dunleavy Apr 6, 2026 5:00am